Multidomain Targeting of BCR-Abl by Disruption of Oligomerization and Tyrosine Kinase Inhibition: Toward Eradication of CML

Molecular Pharmaceutics- United States

doi 10.1021/mp400323c

Full Text

Abstract

Available in

Date

Authors

Publisher

American Chemical Society (ACS)

Related search

Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

BCR-ABL Tyrosine Kinase

Science-Business eXchange
2012English

Inhibition of BCR Serine Kinase by Tyrosine Phosphorylation.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1996English

Evolution of BCR/ABL Gene Mutation in CML Is Time Dependent and Dependent on the Pressure Exerted by Tyrosine Kinase Inhibitor

PLoS ONE
Multidisciplinary
2015English

Oligomerization Inhibition, Combined With Allosteric Inhibition, Abrogates the Transformation Potential of T315i-Positive BCR/ABL

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Oligomerization of the ABL Tyrosine Kinase by the Ets Protein TEL in Human Leukemia.

Molecular and Cellular Biology
Cell BiologyMolecular Biology
1996English

Tyrosine Kinase Inhibitors in BCR-ABL Positive Acute Lymphoblastic Leukemia

Haematologica
Hematology
2015English

Regulation of BCR-Abl-Induced SAP Kinase Activity and Transformation by the SHPTP1 Protein Tyrosine Phosphatase

Oncogene
Cancer ResearchGeneticsMolecular Biology
1998English

Targeting the SH2-Kinase Interface in BCR-Abl Inhibits Leukemogenesis

Cell
BiochemistryGeneticsMolecular Biology
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy